EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY-NC 4.0

Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum: 2023 Revised Korean Thyroid Association Guidelines

Hwa Young Ahn, Ka Hee Yi

Endocrinology and Metabolism · 2023

DOI: 10.3803/enm.2023.1696 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, 2023. Verfasst von Hwa Young Ahn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Abortion, Spontaneous, Pregnancy Complications, Premature Birth, Thyroid Diseases. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid hormone plays a critical role in fetal growth and development, and thyroid dysfunction during pregnancy is associated with several adverse outcomes, such as miscarriage and preterm birth. In this review, we introduce and explain three major changes in the revised Korean Thyroid Association (KTA) guidelines for the diagnosis and management of thyroid disease during pregnancy: first, the normal range of thyroid-stimulating hormone (TSH) during pregnancy; second, the treatment of subclinical hypothyroidism; and third, the management of euthyroid pregnant women with positive thyroid autoantibodies. The revised KTA guidelines adopt 4.0 mIU/L as the upper limit of TSH in the first trimester. A TSH level between 4.0 and 10.0 mIU/L, combined with free thyroxine (T4) within the normal range, is defined as subclinical hypothyroidism, and a TSH level over 10 mIU/L is defined as overt hypothyroidism regardless of the free T4 level. Levothyroxine treatment is recommended when the TSH level is higher than 4 mIU/L in subclinical hypothyroidism, regardless of thyroid peroxidase antibody positivity. However, thyroid hormone therapy to prevent miscarriage is not recommended in thyroid autoantibody-positive women with normal thyroid function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abortion, SpontaneousPregnancy ComplicationsPremature BirthThyroid DiseasesHypothyroidismFemaleInfant, NewbornPregnancyHumansThyrotropinPostpartum PeriodThyroid HormonesRepublic of Korea

Stichwörter der Autor:innen

Anti-thyroid autoantibodiesHypothyroidismPregnancy

Substanzen

ThyrotropinThyroid Hormones

Autor:innen und Institutionen

  • Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.

Zitieren

APA

Ahn, H. Y., & Yi, K. H. (2023). Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum: 2023 Revised Korean Thyroid Association Guidelines. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2023.1696

Vancouver

Ahn HY, Yi KH. Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum: 2023 Revised Korean Thyroid Association Guidelines. Endocrinology and Metabolism. 2023. doi:10.3803/enm.2023.1696

BibTeX
@article{Ahn2023,
  author = {Ahn, Hwa Young and Yi, Ka Hee},
  title = {Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum: 2023 Revised Korean Thyroid Association Guidelines},
  journal = {Endocrinology and Metabolism},
  year = {2023},
  doi = {10.3803/enm.2023.1696}
}
Kostenlos starten →